Linked Life Data

1355640

Source:http://linkedlifedata.com/resource/pubmed/id/1355640

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1992-10-6
pubmed:abstractText
In a randomized double-blind multicenter clinical study, 116 children with asthma were randomly assigned to treatment with an inhaled beta-2-agonist (salbutamol 0.2 mg) plus an inhaled corticosteroid (budesonide 0.2 mg) three times a day (BA+CS) or to an inhaled beta-2-agonist (salbutamol 0.2 mg) plus a placebo three times a day (BA+PL). After a median follow-up time of 22 months, 26 patients receiving BA+PL (45%) had withdrawn from randomized treatment, mainly because of asthma symptoms, compared with three withdrawals in the patients receiving BA+CS (p less than 0.0001). The FEV1, expressed as a percentage of the predicted value for age, sex, and height, showed an absolute increase of 7.0% after 2 months of BA+CS compared with a decrease of 4.0% after 2 months of BA+PL. This 11% difference in percent predicted FEV1 (95% confidence interval, 7 to 15%; p less than 0.0001) was then maintained after a median follow-up period of 22 months. Postbronchodilator FEV1 showed an absolute increase of 3.7% predicted within 2 months in patients receiving BA+CS and an absolute decrease of 1.1% predicted in children receiving BA+PL (p = 0.0005). Thereafter, this difference between the two treatment groups was maintained. Average peak expiratory flow rate (PEFR) increased from baseline by 36.6 L/min in the BA+CS group compared with 3.7 L/min in the BA+PL group (p = 0.003). This difference then remained for the median follow-up time of 22 months.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0003-0805
pubmed:author
pubmed:issnType
Print
pubmed:volume
146
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
547-54
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1355640-Administration, Inhalation, pubmed-meshheading:1355640-Adolescent, pubmed-meshheading:1355640-Adrenal Cortex Hormones, pubmed-meshheading:1355640-Adrenergic beta-Agonists, pubmed-meshheading:1355640-Albuterol, pubmed-meshheading:1355640-Asthma, pubmed-meshheading:1355640-Bronchodilator Agents, pubmed-meshheading:1355640-Budesonide, pubmed-meshheading:1355640-Child, pubmed-meshheading:1355640-Double-Blind Method, pubmed-meshheading:1355640-Drug Evaluation, pubmed-meshheading:1355640-Drug Therapy, Combination, pubmed-meshheading:1355640-Forced Expiratory Volume, pubmed-meshheading:1355640-Glucocorticoids, pubmed-meshheading:1355640-Humans, pubmed-meshheading:1355640-Lung, pubmed-meshheading:1355640-Peak Expiratory Flow Rate, pubmed-meshheading:1355640-Pregnenediones, pubmed-meshheading:1355640-Time Factors
pubmed:year
1992
pubmed:articleTitle
Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.
pubmed:affiliation
Department of Pediatrics, Erasmus University of Rotterdam.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't